Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited announced it will host a webinar to discuss Pivalate, a novel radiotracer for detecting relapsed brain metastases from solid tumors. Pivalate targets fatty acid synthase, which is overexpressed by tumors, offering a potentially transformative approach in imaging and monitoring brain metastases, addressing limitations of current technologies like FDG PET and MRI.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company that develops innovative radiopharmaceutical products for diagnostic and therapeutic applications, focusing on areas with high unmet medical needs. The company is listed on ASX and NASDAQ and has a pipeline of distinct platform technologies, including peptides, small molecules, and monoclonal antibodies for cancer treatment.
Average Trading Volume: 3,510,710
Technical Sentiment Signal: Hold
Current Market Cap: A$73.31M
See more insights into RAD stock on TipRanks’ Stock Analysis page.